Use of phage display for the generation of human antibodies that neutralize factor IXa function

Blood Coagulation and Fibrinolysis

Volumn 11, Issue 1, 2000, Pages 27-42

  Suggett, S ^a   Kirchhofer, D ^a   Hass, P ^a   Lipari, T ^a   Moran, P ^a   Nagel, M ^a   Judice, K ^b   Schroeder, K ^a   Tom, J ^a   Lowman, H ^a   Adams, C ^a   Eaton, D ^a   Devaux, Brigitte ^a  

^a GENENTECH INC   (United States)

^b Advanced Medicine Inc   (United States)

Author keywords

Blood coagulation; Factor IX; Human antibodies; Phage display

Indexed keywords

BLOOD CLOTTING FACTOR 10; BLOOD CLOTTING FACTOR 9A; IMMUNOGLOBULIN F(AB) FRAGMENT; NEUTRALIZING ANTIBODY;

AMINO ACID SEQUENCE; ANIMAL CELL; ANTIBODY PRODUCTION; ANTIBODY SPECIFICITY; ANTIGEN BINDING; ARTICLE; BACTERIOPHAGE M13; BLOOD CLOTTING; CLONE; CROSS REACTION; DOG; HUMAN; MOUSE; NONHUMAN; PARTIAL THROMBOPLASTIN TIME; PHAGE DISPLAY; PRIORITY JOURNAL; RABBIT; SCREENING; SEQUENCE HOMOLOGY;

EID: 0033950343     PISSN: 09575235     EISSN: None     Source Type: Journal    
DOI: 10.1097/00001721-200001000-00004     Document Type: Article

References (78)

1. 1 Berkower I. The promise and pitfalls of monoclonal antibody therapeutics. Curr Opin Biotechnol 1996; 7: 622-628.
2. 2 Sears HF, Herlyn D, Steplewski Z, Koprowski H. Effects of monoclonal antibody immunotherapy on patients with gastrointestinal adenocarcinoma. J Biol Response Mod 1984; 3: 138-150.
3. 3 Shawler DL, Bartholomew RM, Smith LM, Dillman RO. Human immune response to multiple injections of murine monoclonal IgG. J Immunol 1985; 135: 1530-1535.
4. 4 Jaffers GJ, Fuller TC, Cosimi AB, Russell PS, Winn HJ, Colvin RB. Monoclonal antibody therapy: anti-idiotypic and non-anti-idiotypic antibodies to OKT3 arising despite intense immunosuppression. Transplantation 1986; 41: 572-578.
5. 5 Hakimi J, Chizzonite R, Luke DR, Familletti PC, Bailon P, Kondas JA, et al. Reduced immunogenicity and improved pharmacokinetics of humanized anti-Tac in cynomolgous monkeys. J Immunol 1991; 147: 1352-1359.
6. 6 Riechman L, Clark M, Waldmann H, Winter G. Reshaping human antibodies for therapy. Nature 1988; 332: 323-327.
7. 7 Junghans RP, Waldmann TA, Landolfi NF, Avdalovic NM, Schneider WP, Queen C. Anti-Tac-H, a humanized antibody to the interleukin-2 receptor with new features for immunotherapy in malignant and immune disorders. Cancer Res 1990; 50: 1495-1502.
8. 8 Boulianne GL, Hozumi N, Shulman MJ. Production of functional chimaeric mouse/human antibody. Nature 1984; 312: 643-646.
9. 9 Morrison SL, Johnson MJ, Herzenberg LA, Oi VT. Chimaeric human antibody molecules: mouse antigen-binding domains with human constant region domains. Proc Natl Acad Sci USA 1984; 81: 6851-6855.
10. 10 Coller BS. Platelet GPIIb/IIIa antagonists: the first anti-integrin receptor therapeutics. J Clin Invest 1997; 99: 1467-1471.
11. 11 Newman R, Albert J, Anderson D, Carner K, Heard C, Norton F. 'Primatization' of recombinant antibodies for immunotherapy of human diseases: a macaque/human chimeric antibody against CD4. Bio/ Technology 1992; 10: 1455-1460.
12. 12 Jones PT, Dear PH, Foote J, Neuberger MS, Winter G. Replacing the complementary-determining regions in human antibody with those from a mouse. Nature 1986; 321: 522-525.
13. 13 Dalesandro MR, Pak K-Y, Tam S, Wilson E, Looney JE, Knight DM, et al. Effects of isotype and Fc region on in vitro function of a mouse/human chimeric CD4 antibody. Int Immunol 1993; 5: 283-291.
14. 14 Werther WA, Gonzalez TN, O'Connor SJ, McCabe S, Chan B, Hotaling T, et al. Humanization of an anti-lymphocyte function-associated antigen (LFA)-1 monoclonal antibody and reengineering of the humanized antibody for binding to rhesus LFA-1. J Immunol 1996; 157: 4986-4995.
15. 15 Presta LG, Chen H, O'Connor SJ, Chisholm V, Meng G, Krummen L, et al. Humanization of an anti-vascular endothelial growth factor monoclonal antibody for the therapy of solid tumors and other disorders. Cancer Res 1997; 57: 4593-4599.
16. 16 Presta LG, Lahr SJ, Shields RL, Porter JP, Gorman CM, Fendly BM, et al. Humanization of an antibody directed against IgE. J Immunol 1993; 151: 2623-2632.
17. 17 Sherman-Gold R. Monoclonal antibodies: the evolution from '80s magic bullets to mature, mainstream applications as clinical therapeutics. Genetic Eng News 1997; 17(14): 4-7
18. 18 Heusser C, Jardieu P. Therapeutic potential of anti-IgE antibodies. Curr Opin Immunol 1997; 9: 805-813.
19. 19 Shields RL, Whether WR, Zioncheck K, O'Connell L., Fendly B, Presta LG, et al. Inhibition of allergic reactions with antibodies to IgE. Int Arch Allergy Immunol 1995; 107:308-312.
20. 20 Vincenti F, Kirkman R, Light S, Bumgardner G, Pescovitz M, Halloran P, et al. Interleukin-2-receptor blockade with Daclizumab to prevent acute rejection in renal transplantation. N Engl J Med 1998; 338: 161-165.
21. 21 Baselga J, Tripathy D, Mendelsohn J, Baughman S, Benz CC, Dantis L, et al. Phase II study of weekly intravenous recombinant humanized anti-p185HER2 monoclonal antibody in patients with HER2/neu over-expressing metastatic breast cancer. J Clin Oncol 1996; 14: 737-744.
22. 22 Maloney DG, Grillo-Lopez AJ, White CA, Bodkin D, Schilder RJ, Neidhart JA, et al. IDEC-C2B8 (Rituximab) anti-CD20 monoclonal antibody therapy in patients with relapsed low-grade non-Hodgkin's B-cell lymphoma. Blood 1997; 90: 2188-2195.
23. 23 Vaughan TJ, Williams AJ, Pritchard K, Osbourn JK, Pope AR, Earnshaw JC, et al. Human antibodies with sub-nanomolar affinities isolated from a large non-immunized phage display library. Nature Biotechnol 1996; 14: 309-314.
24. 24 Winter G, Griffiths AD, Hawkins RE, Hoogenboom HR. Making antibodies by phage display technology. Annu Rev Immunol 1994; 12: 433-455.
25. 25 Smith GP. Filamentous fusion phage: novel expression vectors that display cloned antigens on the virion surface. Science 1985; 228: 1315-1317.
26. 26 McCafferty J, Griffiths AD, Winter G, Chiswell DJ. Phage antibodies: filamentous phage displaying antibody variable domains. Nature 1990; 348: 552-554.
27. 27 Hoogenboom HR, Griffiths AD, Johnson KS, Chiswell DJ, Hudson P, Winter G. Multi-subunit proteins on the surface of filamentous phage: methodologies for displaying antibody (Fab) heavy and light chains. Nucl Acids Res 1991; 19: 4133-4137.
28. 28 Kang AS, Barbas CF, Janda KD, Benkovic SJ, Lerner RA. Linkage of recognition and replication functions by assembling combinatorial antibody Fab libraries along phage surfaces. Proc Natl Acad Sci USA 1991; 88: 4363-4366.
29. 29 Breitling F, Dubel S, Seehaus T, Klewinghaus I, Little M. A surface expression vector for antibody screening. Gene 1991; 104: 147-153.
30. 30 Barbas CF, Kang AS, Lerner RA, Benkovic SJ. Assembly of combinatorial antibody libraries on phage surfaces: the gene III site. Proc Natl Acad Sci USA 1991; 88: 7978-7982.
31. 31 Wu H, Goud GN, Sierks MR. Artificial antibodies for affinity chromatography of homologous proteins: application to blood clotting proteins. Biotechnol Prog 1998; 14: 496-499.
32. 32 Benedict CR, Ryan J, Wolitzky B, Ramos R, Gerlach M, Tijburg P, et al. Active site-blocked factor IXa prevents intravascular thrombus formation in the coronary vasculature without inhibiting extravascular coagulation ina canine thrombosis model. J Clin Invest 1991; 88: 1760-1765.
33. 33 Wong AG, Gunn AC, Ku P, Hollenbach SJ, Sinha U. Relative efficacy of active site-blocked factors IXa, Xa in models of rabbit venous and arterio-venous thrombosis. Thromb Haemost 1997; 77: 1143-1147.
34. 34 Spanier TB, Oz MC, Minanov OP, Simantov R, Kisiel W, Stern DM, et al. Heparinless cardiopulmonary bypass with active-site blocked factor IXa: a preliminary study in the dog. J Thoracic Cardiovasc Surg 1998; 115: 1179-1188.
35. 35 Davie EW. Biochemical and molecular aspects of the coagulation cascade. Thromb Haemost 1995; 74: 1-6.
36. 36 Mann KG, Krishnaswamy S, Lawson JH. Surface-dependent hemostasis. Sem Haematol 1992; 29: 213-226.
37. 37 Cheung W-F, Van den Born J, Kuhn K, Kjellen L, Hudson BH, Stafford DW. Identification of the endothelial cell binding site for factor IX. Proc Natl Acad Sci USA 1996; 93: 11068-11073.
38. 38 Ahmad SS, Rawala-Sheikh R, Cheung W-F, Jameson BA, Stafford DW, Walsh PN. High-affinity specific factor IXa binding to platelets is mediated in part by residues 3-11. Biochemistry 1994; 33: 12048-12055.
39. 39 Ahmad SS, Wong MY, Rawala R, Jameson BA, Walsh PN. Coagulation Factor IX residues G4-G11 mediate its interaction with a shared Factor IX/IXa binding site on activated platelets but not the assembly of the functional Factor X activating complex. Biochemistry 1998; 37: 1671-1679.
40. 40 Cheung W-F, Hamaguchi N, Smith KJ, Stafford DW. The binding of human factor IX to endothelial cells is mediated by residues 3-11. J Biol Chem 1992; 267: 20529-20531.
41. 41 Rawala-Sheikh R, Ahmad SS, Monroe DM, Roberts HR, Walsh PN. Role of g-carboxyglutamic acid residues in the binding of factor IXa to platelets and in factor-X activation. Blood 1992; 79: 398-405.
42. 42 Ryan J, Wolitzky B, Heimer E, Lambrose T, Felix A, Tam JP, et al. Structural determinants of the factor IX molecule mediating interaction with the endothelial cell binding site are distinct from those involved in phospholipid binding. J Biol Chem 1989; 264: 20283-20287.
43. 43 Toomey JR, Smith KJ, Roberts HR, Stafford DW. The endothelial cell binding determinant of human factor IX resides in the g-carboxyglutamic acid domain. Biochemistry 1992; 31: 1806-1808.
44. 44 Prorok M, Geng J-P, Warder SE, Castellino FJ. The entire g-carboxyglutamic acid and helical stack-domains of human coagulation factor IX are required for optimal binding to its endothelial cell receptor. Int J Peptide Prot Res 1996; 48: 281-285.
45. 45 Liebman HA. The metal-dependent conformational changes in factor IX associated with phospholipid binding. Eur J Biochem 1993; 212: 339-345.
46. 46 Liebman HA, Furie BC, Furie B. The factor IX phospholipid-binding site is required for calcium-dependent activation of factor IX by factor XIa. J Biol Chem 1987; 262: 7605-7612.
47. 47 Cheung W-F, Wolberg AS, Stafford DW, Smith KJ. Localization of a metal-dependent epitope to the amino terminal residues 33-40 of human Factor IX. Thromb Res 1995; 80: 419-427.
48. 48 Sugo T, Mizuguchi J, Kamikubo Y, Matsuda M. Anti-human factor IX monoclonal antibodies specific for calcium ion-induced conformations. Thromb Res 1990; 58: 603-614.
49. 49 Wojcik EGG, Cheung W-F, van den Berg M, van der Linden IK, Stafford DW, Bertina RM. Identification of residues in the Gla-domain of human factor IX involved in the binding to conformation. Biochim Biophys Acta 1998; 1382: 91-101.
50. 50 Cheung W-F, Stafford DW, Sugo T. Localization of a calcium-dependent epitope to the amino terminal region of the Gla domain of human Factor IX. Thromb Res 1996; 81: 65-73.
51. 51 Kates SA, Daniels SB, Albericio F. Automated allyl cleavage for continuous-flow synthesis of cyclic and branched peptides. Anal Biochem 1993; 212: 303-310.
52. 52 Hawkins RE, Russell SJ, Baier M, Winter G. Selection of phage antibodies by binding affinity: mimicking affinity maturation. J Mol Biol 1992; 226: 889-896.
53. 53 Carter P, Kelley RF, Rodrigues ML, Snedecor B, Covarrubias M, Velligan MD, et al. High level Escherichia coli expression and production of a bivalent humanized antibody fragment. Bio/Technology 1992; 10: 163-167.
54. 54 Kostelny SA, Cole MS, Tso JY. Formation of a bispecific antibody by the use of leucine zippers. J Immunol 1992; 148: 1547-1553.
55. 55 Hoffmann A, Roeder RG. Purification of his-tagged proteins in non-denaturing conditions suggests a convenient method for protein interactions studies. Nucl Acids Res 1991; 19: 6337-6338.
56. 56 Lofas S, Johnsson B. A novel hydrogel matrix on gold surfaces in surface plasmon resonance sensors for fast and efficient covalent immobilization of ligands. J Chem Soc Commun 1990; 21: 1526-1528.
57. 57 Marcum JA, Atha DH, Fritze LMS, Nawroth P, Stern D, Rosenberg RD. Cloned bovine aortic endothelial cells synthesize anticoagulantly active heparan sulfate proteoglycan. J Biol Chem 1986; 261: 7507-7517.
58. 58 Janson TL, Stormorken H, Prydz H. Species specificity of tissue thromboplastin. Haemostasis 1984; 14: 440-444.
59. 59 Dennis MS, Henzel WJ, Pitti RM, Lipari MT, Napier MA, Deisher TA, et al. Platelet glycoprotein IIb-IIIa protein antagonists from snake venoms: evidence for a family of platelet-aggregation inhibitors. Proc Natl Acad Sci USA 1990; 87: 2471-2475.
60. 60 Mimms LT, Zampighi G, Nozaki Y, Tanford C, Reynolds JA. Phospholipid vesicle formation and transmembrane protein incorporation using octyl glucoside. Biochemistry 1981; 20: 833-840.
61. 61 Griffiths AD, Malmqvist M, Marks JD, Bye JM, Embleton MJ, McCafferty J, et al. Human anti-self antibodies with high specificity from phage display libraries. EMBO J 1993; 12: 725-734.
62. 62 Freedman SJ, Furie BC, Furie B, Baleja JD. Structure of the calcium ion-bound g-carboxyglutamic acid-rich domain of factor IX. Biochemistry 1995; 34: 12126-12137.
63. 63 Freedman SJ, Blostein MD, Baleja JD, Jacobs M, Furie BC, Furie B. Identification of the phospholipid binding site in the vitamin K-dependent blood coagulation factor IX. J Biol Chem 1996; 271: 16227-16236.
64. 64 Merchant AM, Zhu Z, Yuan JQ, Goddard A, Adams CW, Presta LG, et al. An efficient route to human bispecific IgG. Nature Biotechnol 1998; 16: 677-681.
65. 65 Chothia C, Lesk AM, Tramontano A, Levitt M, Smith-Gill SJ, Air G, et al. Conformations of immuno-globulin hyper-variable regions. Nature 1989; 342: 877-883.
66. 66 Schier R, McCall A, Adams GP, Marshall KW, Merritt H, Yim M, et al. Isolation of picomolar affinity anti-cerbB-2 single-chain Fv by molecular evolution of the complementarity determining regions in the center of the antibody binding site. J Mol Biol 1996; 263: 551-567.
67. 67 Heimark RL, Schwanz SM. Binding of coagulation factors IX and X to the endothelial cell surface. Biochem Biophys Res Commun 1983; 111: 723-731.
68. 68 Stern DM, Drillings M, Nossel HL, Hurlet-Jensen A, LaGamma KS, Owen J. Binding of factors IX and IXa to cultured vascular endothelial cells. Proc Natl Acad Sci USA 1983; 80: 4119-4123.
69. 69 Blackburn MN, Church WR, Patel A, Valocik R, Baker A., Koster P, et al. Anti-factor IX monoclonal antibody, BC2, is a potent antithrombotic agent. Blood 1997; 90: 424a-425a.
70. 70 Refino CJ, Himber J, Burcklen L, Moran P, Peek M, Suggett S, et al. A human antibody that binds to the γ-carboxyglutamic acid domain of Factor IX is a potent antithrombotic in vivo. Thrombo Haemost 1999; 82: 1188-1195.
71. 2+ion and membrane binding structure of the Gla domain of Ca-prothrombin fragment 1. Biochemistry 1992; 31: 2554-2566.
72. 72 Banner DW, D'Arcy A, Chene C, Winkler FK, Guha A, Konigsberg WH, et al. The crystal structure of the complex of blood coagulation factor VIIa with soluble tissue factor. Nature 1996; 380: 41-46.
73. 2+ binding to the first EGF domain. A combined nMR-small angle X-ray scattering study. Biochemistry 1996; 35: 11547-11559.
74. 74 Kurachi K, Davie EW. Isolation and characterization of a cDNA coding for human factor IX gene. Proc Natl Acad Sci USA 1982; 79: 6461-6464.
75. 75 Evans JP, Watzke HH, Ware JL, Stafford DW, High K. Molecular cloning of cDNA encoding canine factor IX. Blood 1989; 74: 207-212.
76. 76 Wu SM, Stafford DW, Ware JL. Deduced amino acid sequence of mouse blood coagulation factor IX. Gene 1990; 86: 275-278.
77. 77 Pendurthi UR, Tukey RH, Vijaya Mohan Rao L. Characterization of a rabbit factor IX cDNA. Thromb Res 1992; 65: 177-186.
78. 78 Stenflo J, Dahlback B. Vitamin-K dependent proteins. In: The molecular basis of blood diseases, 2nd edition. Philadelphia, PA: W. B. Saunders, Company; 1994. pp. 565-598.